HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

SK&F 82958 (SKF 82958)

Also Known As:
SKF 82958; 6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine; Cl-APB; SK&F-82958; SKF-82958
Networked: 19 relevant articles (4 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Langley, Robert R: 1 article (05/2013)
2. Bottsford-Miller, Justin: 1 article (05/2013)
3. Shahzad, Mian M K: 1 article (05/2013)
4. Sood, Anil K: 1 article (05/2013)
5. Cole, Steve W: 1 article (05/2013)
6. Kang, Yu: 1 article (05/2013)
7. Siddik, Zahid H: 1 article (05/2013)
8. Allen, Julie K: 1 article (05/2013)
9. Matsuo, Koji: 1 article (05/2013)
10. Moreno-Smith, Myrthala: 1 article (05/2013)

Related Diseases

1. Dyskinesias (Dyskinesia)
2. Parkinsonian Disorders (Parkinsonism)
3. Parkinson Disease (Parkinson's Disease)
03/01/1999 - "The aim of this study was twofold: (1) to study the predictive validity of the drug-naive, bilaterally MPTP-treated monkey as an animal model of Parkinson's disease (PD), and (2) to investigate the therapeutic and undesired effects of the D1 agonist SKF 82958 as compared to L-DOPA treatment, in drug-naive and L-DOPA pretreated monkeys. "
10/06/2000 - "To determine if this phenomenon generalizes to other motor behaviors, we have used this rat model of Parkinson's disease to examine the effects of the direct dopamine D(1) receptor agonist SKF 82958 and the indirect DA agonist L-3,4-dihydroxyphenylalanine (L-DOPA) on the acoustic startle response. "
03/01/1999 - "The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958."
06/09/2000 - "In this study we demonstrate that SB 206553 (5-methyl-1-(3-pyridylcarbamoyl)-1,2,3, 5-tetrahydropyrrol[2,3-f]indole) (20 mg/kg) enhanced the actions of the dopamine D(1) receptor agonist, SKF 82958 ((+)-6-chloro-7, 8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide) (1 mg/kg), in eliciting locomotion in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. "
02/01/1995 - "The effects of co-administration of quinpirole with benzazepine D1 dopamine (DA) agonists possessing full/supramaximal (SKF 80723 and SKF 82958), partial (SKF 38393 and SKF 75670) and no efficacies (SKF 83959) in stimulating adenylate cyclase (AC) were investigated in rodent and primate models of Parkinson's disease (PD). "
4. Seizures (Seizure)
5. Neurologic Manifestations (Neurological Manifestations)

Related Drugs and Biologics

1. 1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
2. Quinpirole
3. Dopamine (Intropin)
4. Levodopa (L Dopa)
5. SB 206553
6. indole
7. 2,3,4,5- Tetrahydro- 7,8- dihydroxy- 1- phenyl- 1H- 3- benzazepine (SKF 38393)
8. A 77636
9. Fenoldopam (Corlopam)
10. Dopamine Agonists (Dopamine Agonist)

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)